DK0612248T3 - Præparat, der indeholder cisplatin og topotecan som antitumormiddel - Google Patents

Præparat, der indeholder cisplatin og topotecan som antitumormiddel

Info

Publication number: DK0612248T3
Authority: DK; Denmark
Prior art keywords: human; topotecan; composition containing; compound; antitumor agent
Prior art date: 1991-11-15

Application number

DK92925253T

Other languages

English (en)

Inventor

Randall Keith Johnson

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-15

Filing date

1992-11-13

Publication date

2003-12-08

1992-11-13 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2003-12-08 Application granted granted Critical

2003-12-08 Publication of DK0612248T3 publication Critical patent/DK0612248T3/da

Links

239000002246 antineoplastic agent Substances 0.000 title 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title 1
229960004316 cisplatin Drugs 0.000 title 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 title 1
229960000303 topotecan Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
230000002401 inhibitory effect Effects 0.000 abstract 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 4
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
229910052697 platinum Inorganic materials 0.000 abstract 2
210000004881 tumor cell Anatomy 0.000 abstract 2
230000004565 tumor cell growth Effects 0.000 abstract 2
230000004614 tumor growth Effects 0.000 abstract 2
239000003085 diluting agent Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Seasonings (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK92925253T 1991-11-15 1992-11-13 Præparat, der indeholder cisplatin og topotecan som antitumormiddel DK0612248T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US79304191A	1991-11-15	1991-11-15
PCT/US1992/009864 WO1993009782A1 (en)	1991-11-15	1992-11-13	Combination chemotherapy

Publications (1)

Publication Number	Publication Date
DK0612248T3 true DK0612248T3 (da)	2003-12-08

Family

ID=25158913

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92925253T DK0612248T3 (da)	1991-11-15	1992-11-13	Præparat, der indeholder cisplatin og topotecan som antitumormiddel

Country Status (14)

Country	Link
US (1)	US5633016A (da)
EP (3)	EP1393730A3 (da)
JP (1)	JPH07501079A (da)
AT (1)	ATE247471T1 (da)
AU (1)	AU671605B2 (da)
CA (1)	CA2123321C (da)
DE (1)	DE69233169T2 (da)
DK (1)	DK0612248T3 (da)
ES (1)	ES2204894T3 (da)
MX (1)	MX9206577A (da)
NZ (1)	NZ245112A (da)
PT (1)	PT101061B (da)
WO (1)	WO1993009782A1 (da)
ZA (1)	ZA928771B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552154A (en)	1989-11-06	1996-09-03	The Stehlin Foundation For Cancer Research	Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
WO1993009782A1 (en) *	1991-11-15	1993-05-27	Smithkline Beecham Corporation	Combination chemotherapy
EP0678025B1 (en) *	1993-01-15	1998-04-15	The Stehlin Foundation For Cancer Research	Transdermal treatment of cancer with water-insoluble s-camptothecin of the closed lactone ring form
EP0715854B1 (en)	1994-11-11	2003-09-10	Debiopharm S.A.	Carcinostatic compositions containing cis-oxaliplatinum and one or more other compatible carcinostatic substances
US6274576B1 (en)	1995-06-27	2001-08-14	The Henry Jackson Foundation For The Advancement Of Military Medicine	Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
CA2225682A1 (en) *	1995-06-27	1997-01-16	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9804013D0 (en)	1998-02-25	1998-04-22	Sanofi Sa	Formulations
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1044977B1 (en) *	1999-03-09	2002-05-02	Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.	Camptothecin derivatives having antitumor activity
US7105492B2 (en) *	1999-03-09	2006-09-12	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Camptothecin derivatives having antitumor activity
AU3755800A (en) *	1999-03-15	2000-10-04	Introgen Therapeutics, Inc.	Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1754488A1 (en)	1999-05-24	2007-02-21	Introgen Therapeutics, Inc.	Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
CA2385528C (en)	1999-10-01	2013-12-10	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6420378B1 (en) *	1999-10-15	2002-07-16	Supergen, Inc.	Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
AU2001243515A1 (en)	2000-03-08	2001-09-17	Rhode Island Hospital, A Lifespan Partner	Combination drug therapy
US6545010B2 (en) *	2000-03-17	2003-04-08	Aventis Pharma S.A.	Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
US10293056B1 (en)	2000-05-24	2019-05-21	Board Of Regents, The University Of Texas System	Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
DE10032256C2 (de) *	2000-07-03	2003-06-05	Infineon Technologies Ag	Chip-ID-Register-Anordnung
CA2429769C (en) *	2000-12-07	2016-04-26	Board Of Regents, The University Of Texas System	Methods of treatment involving human mda-7
US6476068B1 (en)	2001-12-06	2002-11-05	Pharmacia Italia, S.P.A.	Platinum derivative pharmaceutical formulations
EP1490101A4 (en) *	2002-03-05	2006-09-20	Univ Texas	PROCESS FOR IMPROVING IMMUNE INDUCTION WITH MDA-7
EP2269619A1 (en)	2002-08-12	2011-01-05	Jennerex Biotherapeutics ULC	Methods and compositions concerning poxviruses and cancer
BRPI0408063A (pt) *	2003-03-03	2006-02-14	Univ Texas	métodos e composições envolvendo mda-7
US8034790B2 (en) *	2003-12-01	2011-10-11	Introgen Therapeutics	Use of MDA-7 to inhibit pathogenic infectious organisms
US20070281041A1 (en) *	2004-03-02	2007-12-06	Introgen Therapeutics, Inc.	Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CA2597329C (en) *	2005-02-08	2016-10-11	Board Of Regents, The University Of Texas System	Compositions and methods involving mda-7 for the treatment of cancer
US8668905B2 (en) *	2005-05-12	2014-03-11	University Of South Florida	P53 vaccines for the treatment of cancers
US20100190180A1 (en) *	2005-07-06	2010-07-29	Heidi Kay	Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression
CN101351213B (zh) *	2005-09-07	2013-10-02	詹纳里克斯公司	使用表达gm-csf的痘病毒系统性治疗转移性癌和/或全身散布性癌
US8980246B2 (en)	2005-09-07	2015-03-17	Sillajen Biotherapeutics, Inc.	Oncolytic vaccinia virus cancer therapy
WO2007092944A2 (en) *	2006-02-08	2007-08-16	Introgen Therapeutics, Inc.	Compositions and methods involving gene therapy and proteasome modulation
US20110028536A1 (en) *	2006-08-18	2011-02-03	Gjerset Ruth A	Methods and compositions for topoisomerase i modulated tumor suppression
US8178564B2 (en) *	2006-11-06	2012-05-15	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8173686B2 (en)	2006-11-06	2012-05-08	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168661B2 (en) *	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168662B1 (en)	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) *	2009-08-05	2011-02-10	Poniard Pharmaceuticals, Inc.	Stabilized picoplatin oral dosage form
KR20080084528A (ko)	2007-03-15	2008-09-19	제네렉스 바이오테라퓨틱스 인크.	종양살상형 백시니아 바이러스 암 치료
US20100260832A1 (en) *	2007-06-27	2010-10-14	Poniard Pharmaceuticals, Inc.	Combination therapy for ovarian cancer
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
WO2009011861A1 (en) *	2007-07-16	2009-01-22	Poniard Pharmaceuticals, Inc.	Oral formulations for picoplatin
EP2249644A4 (en) *	2008-02-08	2012-05-30	Poniard Pharmaceuticals Inc	PICOPLATIN AND AMRUBICIN FOR THE TREATMENT OF LUNG CANCER
ES2671570T3 (es)	2009-09-14	2018-06-07	Sillajen Biotherapeutics, Inc.	Terapia combinada contra el cáncer con virus oncolítico de vaccinia
DK3012329T3 (da)	2010-06-18	2017-11-20	Myriad Genetics Inc	Fremgangsmåder og materialer til at vurdere tab af heterozygositet
DK2609216T3 (da)	2010-08-24	2016-09-12	Dana Farber Cancer Inst Inc	Fremgangsmåder til at forudsige antikræftreaktion
CN103429258B (zh)	2011-01-04	2016-03-09	新罗杰公司	通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性
EP3693473B1 (en)	2011-06-17	2025-02-19	Myriad Genetics, Inc.	Methods and materials for assessing allelic imbalance
WO2013094581A1 (ja) *	2011-12-21	2013-06-27	株式会社ヤクルト本社	新規なカンプトテシン誘導体
BR112014015152A2 (pt)	2011-12-21	2017-07-04	Myriad Genetics Inc	métodos e materiais para a avaliação da perda de heterozigosidade
DK3415915T3 (da)	2012-02-23	2024-11-04	Childrens Medical Center	Fremgangsmåde til at forudsige respons til PARP-inhibitorer
AU2013273466B2 (en)	2012-06-07	2018-11-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
WO2014160080A1 (en)	2013-03-14	2014-10-02	Children's Medical Center Corporation	Cancer diagnosis, treatment selection and treatment
DK2981624T3 (da)	2013-04-05	2020-03-02	Myriad Genetics Inc	Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
EP3073825A4 (en) *	2013-11-25	2017-06-21	The University of Toledo	Inhibitors of ercc1-xpf and methods of using the same
WO2015086473A1 (en)	2013-12-09	2015-06-18	Institut Curie	Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2946251T3 (es)	2014-08-15	2023-07-14	Myriad Genetics Inc	Métodos y materiales para evaluar la deficiencia de recombinación homóloga
EP4141127B1 (en)	2021-08-30	2024-10-09	Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln	Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4342776A (en)	1979-11-05	1982-08-03	Merck & Co., Inc.	4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en)	1981-01-09	1983-08-16	Kabushiki Kaisha Yakult Honsha	7-Substituted camptothecin derivatives
JPS5839685A (ja)	1981-09-04	1983-03-08	Yakult Honsha Co Ltd	新規なカンプトテシン誘導体及びその製造法
US4473692A (en)	1981-09-04	1984-09-25	Kabushiki Kaisha Yakult Honsha	Camptothecin derivatives and process for preparing same
JPS58154582A (ja)	1982-03-10	1983-09-14	Yakult Honsha Co Ltd	新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja)	1983-07-14	1985-01-31	Yakult Honsha Co Ltd	新規なカンプトテシン誘導体
US5004758A (en) *	1987-12-01	1991-04-02	Smithkline Beecham Corporation	Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
DK0418099T3 (da)	1989-09-15	2002-04-02	Res Triangle Inst	Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger
WO1993009782A1 (en) *	1991-11-15	1993-05-27	Smithkline Beecham Corporation	Combination chemotherapy

1992
- 1992-11-13 WO PCT/US1992/009864 patent/WO1993009782A1/en not_active Ceased
- 1992-11-13 DK DK92925253T patent/DK0612248T3/da active
- 1992-11-13 AT AT92925253T patent/ATE247471T1/de not_active IP Right Cessation
- 1992-11-13 DE DE69233169T patent/DE69233169T2/de not_active Expired - Lifetime
- 1992-11-13 EP EP03077641A patent/EP1393730A3/en not_active Withdrawn
- 1992-11-13 ZA ZA928771A patent/ZA928771B/xx unknown
- 1992-11-13 JP JP5509454A patent/JPH07501079A/ja active Pending
- 1992-11-13 AU AU31379/93A patent/AU671605B2/en not_active Expired
- 1992-11-13 ES ES92925253T patent/ES2204894T3/es not_active Expired - Lifetime
- 1992-11-13 NZ NZ245112A patent/NZ245112A/en not_active IP Right Cessation
- 1992-11-13 EP EP03077640A patent/EP1393729A3/en not_active Withdrawn
- 1992-11-13 EP EP92925253A patent/EP0612248B1/en not_active Expired - Lifetime
- 1992-11-13 CA CA002123321A patent/CA2123321C/en not_active Expired - Lifetime
- 1992-11-13 PT PT101061A patent/PT101061B/pt not_active IP Right Cessation
- 1992-11-13 MX MX9206577A patent/MX9206577A/es unknown
1995
- 1995-05-01 US US08/434,897 patent/US5633016A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1393729A2 (en)	2004-03-03
WO1993009782A1 (en)	1993-05-27
DE69233169D1 (de)	2003-09-25
EP1393730A3 (en)	2004-03-17
AU671605B2 (en)	1996-09-05
NZ245112A (en)	1995-07-26
JPH07501079A (ja)	1995-02-02
EP0612248B1 (en)	2003-08-20
ES2204894T3 (es)	2004-05-01
MX9206577A (es)	1993-05-01
US5633016A (en)	1997-05-27
CA2123321A1 (en)	1993-05-27
EP1393729A3 (en)	2004-03-17
CA2123321C (en)	2003-09-30
DE69233169T2 (de)	2004-05-27
PT101061B (pt)	1999-07-30
AU3137993A (en)	1993-06-15
EP1393730A2 (en)	2004-03-03
EP0612248A1 (en)	1994-08-31
ATE247471T1 (de)	2003-09-15
HK1012268A1 (en)	1999-07-30
PT101061A (pt)	1994-06-30
EP0612248A4 (en)	1996-05-08
ZA928771B (en)	1993-09-08

Publication	Publication Date	Title
ATE247471T1 (de)	2003-09-15	Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
IL104006A (en)	1997-02-18	Azaheterocyclylmethyl-chromans their preparation and pharmaceutical compositions containing them
GR1001503B (el)	1994-02-28	Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
IL89840A0 (en)	1989-12-15	Substituted flavonoid compounds and salts thereof,their preparation and pharmaceutical compositions containing them
MY101791A (en)	1992-01-31	New benzimidazole derivatives
PL268927A1 (en)	1989-01-23	Method of obtaining novel derivatives of benzimidazole
EP0344880A3 (en)	1990-04-18	Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
EP0620004A4 (en)	1995-02-01	MEDICAL COMPOSITION.
DE69302838D1 (de)	1996-07-04	Kosmetische und/oder pharmazeutische Zubereitungen und Verfahren zu ihrer Verwendung zum Schutz der Gewebe vor Kontakt mit Schwermetallen
IL91047A0 (en)	1990-02-09	Pharmaceutical compositions containing a zinc complex
GR3033253T3 (en)	2000-09-29	Tri(platinum) complexes
DK166323C (da)	1993-08-30	Griseolsyrederivater og farmaceutiske midler indeholdende disse
JO1406B1 (en)	1986-11-30	Chemical compounds
ZA855822B (en)	1986-03-26	Pharmaceutical compositions for the treatment of involutional brain syndromes and mental decay
DE3474774D1 (en)	1988-12-01	Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
IL106289A (en)	2000-06-01	Phospholipid derivatives their preparation and pharmaceutical compositions containing them
EP0190860A3 (en)	1987-06-03	6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it
DE69233793D1 (de)	2010-09-16	Pharmazeutische Zusammensetzung zur Verwendung in der Behandlung von Eierstockkrebs
EP0173145A3 (en)	1986-03-19	Reduction of the toxic effects caused by anthraquinone drugs
ATE36957T1 (de)	1988-09-15	N,n-diethyl-5-methyl-2h,1-benzothiopyrano-(4,3, - cd)-indazol-2-ethanamine, diese enthaltende zubereitungen und ihre verwendung.
EP0182277A3 (en)	1987-04-22	Pyrazine diazohydroxide compounds and methods for their production and use
MY105876A (en)	1995-02-28	Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer.
JO1519B1 (en)	1989-01-25	New compounds (new benzimidazole derivatives are effective as ulcers)
JO1531B1 (en)	1989-01-25	New near-compounds
ATE227573T1 (de)	2002-11-15	Orale oder intramuskuläre behandlung von pankreaskrebs durch wasserunlösliches s- camptothecin mit geschlossenem lactonring